Latecomer Hilleman Looks To Leverage Cholera Vaccine Advantages
Hilleman Laboratories' CEO believes the Indian venture’s oral cholera vaccine could become the best in its class, telling Scrip cost-effectiveness is critical amid growing budgetary strains and outlining plans for a convenient tablet form.
You may also be interested in...
Vaccine specialist Hilleman announces partnership with another Indian firm, Bharat Biotech, to develop, manufacture and commercialize its simpler and cheaper oral cholera vaccine.
Indian vaccine research organization Hilleman Laboratories says it is hoping to get its "new design", cheaper cholera vaccine licensed in Bangladesh this year and that the next step will be to seek to make it available to UN agencies amid remaining global inoculation need.
Hilleman Laboratories is confident that its oral cholera vaccine, with "multi-fold differentiation" can be manufactured at much lower costs than existing products such as Sanofi-owned Shantha Biotechnics Ltd.'s Shanchol and Valneva SE's Dukoral.